In order to further explore whether EGB761 can improve DKD renal tubular damage, the urine β2-MG and RBP4 levels were tested by ELLSA experiment, and the results shows that EGB761 could decrease the levels of β2 -MG and RBP4; so, the therapeutic effect of EGB761 on DKD was confirmed in vivo experiments. This evidence concerns the gene RBP4 and diabetic kidney disease.